On the evening of Thursday, March 18, a group of Scott City High School students attended the program "Navigating the Hemispheres of Neuroscience" presented by Scott R. Gibbs, MD, FACS and hosted by ...
Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that me ...
Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that m ...
Results Show Continued Safety, Tolerability, and Sustained Clinical Benefit Including Improvements in Function, Physician- and Patient-Reported Outcomes, and Quality-of-Life This Personalized ...
Patients with implanted neural devices offer researchers unique opportunities to study the basic workings of the human brain. This is made possible by patients undergoing epilepsy monitoring or the ...
TDP-43 CYTOPE® preclinical data demonstrates the potential of Prothena’s CYTOPE technology as a novel modality for delivering large molecules into cells, enabling precise targeting of intracellular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results